28.07.2015 - Pfizer has improved the outlook for profits

Pharmaceutical giant Pfizer said yesterday on improving the forecast of earnings growth to 2.01-2.07 dollars per share against 1.95-2.05 per share previously. Recently, the company had to overcome the problems associated with the expiry of patents. The results also were negatively impacted by the strong dollar. As a result, the company announced earnings of 2.63 billion dollars in the second quarter against 2.91 billion in the same period last year. Given the strong market position and strong financial results, we expect growth of the company's shares at 21-25% per annum in the medium term.

RISK WARNING: Trading of complex financial products, such as Stocks, Futures, Foreign Exchange ("Forex"), Contracts for Difference ("CFDs"), Indices, Options, or other financial derivatives, on "margin" carries a high level of risk, and may not be suitable for all investors. The possibility exists that you could sustain a loss of some or all of your initial investment and, therefore, you should not invest money that you cannot afford to lose. You should be aware of all the risks associated with trading these markets, and seek advice from an independent financial advisor if you have any questions or doubts. Please carefully read our full "Risk Disclosure" and "Risk Disclosures for Financial Instruments & Investment Services". FXFINPRO Capital is the trading name of PFX Financial Professionals Limited, a limited liability company formed under the laws of Cyprus, registered with the Registrar of Companies in Nicosia, Cyprus, under nr. HE 237840 and regulated by the Cyprus Securities and Exchange Commission with license number 193/13.